ACE2 News and Research

RSS

Infection with SARS-CoV-2 results in antibodies against common colds

A study published in the journal Science Advances uses electron microscopy-based polyclonal epitope mapping (EMPEM) methodology to elucidate the spike epitopes of β-HCoV targeted by preexisting serum antibodies and compares them to the epitopes targeted by antibodies elicited by SARS-CoV-2 infection using electron microscopy-based polyclonal epitope mapping (EMPEM) methodology.

8 May 2022

Scientists explore immunopathology of COVID-19

Researchers explored the interactions between severe acute respiratory syndrome coronavirus 2 and the host in the development of COVID-19.

6 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Is type 1 diabetes likely to rise after the COVID pandemic?

A recent article posted to the journal Diabetes/Metabolism Research and Reviews explored the risk of a type 1 diabetes wave after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

6 May 2022

miRNAs associated with varying clinical presentations of SARS-CoV-2

A recent article published in the journal iSCIENCE demonstrated different micro ribonucleic acids (miRNAs) linked with various presentations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

5 May 2022

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Researchers assessed the induction of variant-specific neutralizing antibodies against the SARS-CoV-2 spike and nucleocapsid proteins of several SARS-CoV-2 strains.

5 May 2022

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

In a recent study under review in the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (SP) in the thrombi (or blood clots).

5 May 2022

SARS-CoV-2 Omicron BA.2.12.1, BA.4 and BA.5 subvariants are superior to their predecessors

A recent study posted to the bioRxiv* preprint server demonstrated that the latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages evade immunity imparted by the prior subvariants.

5 May 2022

SARS-CoV-2 BA.2 poses greater risk to global health than BA.1

In a recent study published in the journal Cell, researchers investigated distinguishing virological characteristics of Omicron sub-variant BA.2.

3 May 2022

Pets living in households with COVID-19 are high likely to seroconvert and become ill

In a recent study published in the journal Emerging Infectious Diseases, researchers investigated whether pet dogs and cats in the households of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected humans were at risk of infection.

3 May 2022

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

A recent study under review at Nature Portfolio and posted to the Research Square* preprint server depicted how cellular nucleic acid-binding protein (CNBP) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

3 May 2022

Study explores SARS-CoV-2 RNA genome's functional interactions with host cell

In a new study, a worldwide map of the SARS-CoV-2 genome-associated host proteins was developed by a team of researchers using the identification of RNA-binding protein by MS (ChIRP-MS) technique.

3 May 2022

Multi-omics identify COVID-19 severity predictors and prothrombotic signatures in patients with end-stage kidney disease

Researchers demonstrated that plasma levels of leucine-rich repeat-containing 15 are a strong indicator of the severity of COVID-19 in patients with end-stage kidney disease.

3 May 2022

Precision cut slice lung model to study early host viral pathogenesis of SARS-CoV-2 infection

Researchers applied their previously developed precision-cut lung slice model to study the initial events in SARS-CoV-2 pathogenicity in humans.

3 May 2022

Studying immunomodulatory effects of microbiota helps design prophylactic and therapeutic interventions against COVID-19

Researchers reviewed the potential clinically relevant mechanisms by which microbiota and microbiota-derived metabolites influence the host immune responses to SARS-CoV-2 infection.

3 May 2022

Study reveals Omicron sub-lineages BA.4 and BA.5 escape neutralizing antibodies elicited in response to BA.1 infection

Researchers evaluated whether neutralizing immunity elicited against Omicron sub-variant BA.1 in unvaccinated and vaccinated individuals adequately protected against infection by Omicron sub-variants, BA.4 and BA.5.

3 May 2022

Infectivity of SARS-CoV-2 Omicron variant in the intestinal tract

Researchers assessed the infectivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in the intestinal tract.

3 May 2022

Features of SARS-CoV-2 Omicron BA.2 sublineage spike protein

Researchers assessed the traits of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 sublineage spike (S) protein.

3 May 2022

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

A new study published in the journal Gastroenterology used upper and lower gastrointestinal endoscopy to assess whether gut antigen persistence leads to post-acute COVID-19 in patients with or without post-acute COVID-19 symptoms.

3 May 2022

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

Researchers evaluated the importance of the P681 residue within the furin cleavage site of SARS-CoV-2 spike protein in determining the fusogenicity and syncytia formation ability of SARS-CoV-2 strains.

2 May 2022

ACE2 News and Research

Infection with SARS-CoV-2 results in antibodies against common colds

Scientists explore immunopathology of COVID-19

Marine bioactive compounds against SARS-CoV-2

Is type 1 diabetes likely to rise after the COVID pandemic?

miRNAs associated with varying clinical presentations of SARS-CoV-2

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

SARS-CoV-2 Omicron BA.2.12.1, BA.4 and BA.5 subvariants are superior to their predecessors

SARS-CoV-2 BA.2 poses greater risk to global health than BA.1

Pets living in households with COVID-19 are high likely to seroconvert and become ill

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

Study explores SARS-CoV-2 RNA genome's functional interactions with host cell

Multi-omics identify COVID-19 severity predictors and prothrombotic signatures in patients with end-stage kidney disease

Precision cut slice lung model to study early host viral pathogenesis of SARS-CoV-2 infection

Studying immunomodulatory effects of microbiota helps design prophylactic and therapeutic interventions against COVID-19

Study reveals Omicron sub-lineages BA.4 and BA.5 escape neutralizing antibodies elicited in response to BA.1 infection

Infectivity of SARS-CoV-2 Omicron variant in the intestinal tract

Features of SARS-CoV-2 Omicron BA.2 sublineage spike protein

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News